|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2007-10-24
|
|
pubmed:abstractText |
Tumour-induced expansion of regulatory T (T(Reg)) cells is an obstacle to successful cancer immunotherapy. The potential benefit of T(Reg)-cell depletion through the interleukin-2 receptor is lost by the concurrent elimination of activated effector lymphocytes and possibly by the de novo induction of T(Reg)-cell replenishment. In theory, the functional inactivation of T(Reg) cells will maintain them at high numbers in tumours and avoid their replenishment from the peripheral lymphocyte pool, which has the capacity to further suppress the effector lymphocyte anti-tumour response.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adenosine,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Forkhead Transcription Factors,
http://linkedlifedata.com/resource/pubmed/chemical/Foxp3 protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Indoleamine-Pyrrole 2,3,-Dioxygenase,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2 Receptor alpha Subunit,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, OX40,
http://linkedlifedata.com/resource/pubmed/chemical/Tnfrsf4 protein, mouse
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1474-1768
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
7
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
880-7
|
|
pubmed:meshHeading |
pubmed-meshheading:17957190-Adenosine,
pubmed-meshheading:17957190-Animals,
pubmed-meshheading:17957190-Antibodies, Monoclonal,
pubmed-meshheading:17957190-Cell Differentiation,
pubmed-meshheading:17957190-Cell Division,
pubmed-meshheading:17957190-Forkhead Transcription Factors,
pubmed-meshheading:17957190-Humans,
pubmed-meshheading:17957190-Indoleamine-Pyrrole 2,3,-Dioxygenase,
pubmed-meshheading:17957190-Interleukin-2 Receptor alpha Subunit,
pubmed-meshheading:17957190-Lymphocyte Depletion,
pubmed-meshheading:17957190-Mice,
pubmed-meshheading:17957190-Models, Immunological,
pubmed-meshheading:17957190-Neoplasms,
pubmed-meshheading:17957190-Neoplasms, Experimental,
pubmed-meshheading:17957190-Receptors, OX40,
pubmed-meshheading:17957190-Self Tolerance,
pubmed-meshheading:17957190-T-Lymphocyte Subsets,
pubmed-meshheading:17957190-T-Lymphocytes, Regulatory,
pubmed-meshheading:17957190-Thymus Gland
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy.
|
|
pubmed:affiliation |
Fondazione IRCCS Istituto Nazionale Tumori Experimental Oncology, Via G. Venezian 1, Milan, 20133 Italy. mario.colombo@istitutotumori.mi.it
|
|
pubmed:publicationType |
Journal Article,
Review
|
